Staff Contact: Andrew Wheeler
CMS issued a press release about Medicare coverage of monoclonal antibodies directed against amyloid for treatment of Alzheimer’s disease. CMS stated, “At this time, CMS is not reconsidering the national coverage determination for Food and Drug Administration-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease. We recognize that these medications are a unique, new class of drugs, and we regret that the decision could not be more favorable.”
The House Ways and Means Chairman Jason Smith (R-Mo.) and Energy and Commerce Chair Cathy McMorris Rodgers (R-Wash.) issued the following statement: “This is an unprecedented overreach by the administration to override its own FDA. It is setting a troubling precedent for a massive health care bureaucracy to restrict coverage to an entire class of drugs, regardless of the potential for life-saving benefits to patients.”
Selected members of committees issued a letter to HHS Secretary Becerra.